These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30367928)

  • 1. Letter to the Editor Re: "Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later".
    Clark K; Sheehan C; Currow DC
    J Pain Symptom Manage; 2019 Jan; 57(1):e16-e17. PubMed ID: 30367928
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later.
    Campbell ML
    J Pain Symptom Manage; 2019 Jan; 57(1):e14-e15. PubMed ID: 30248383
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to "Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later".
    Boland JW; Currow D; Johnson M
    J Pain Symptom Manage; 2019 Mar; 57(3):e12-e13. PubMed ID: 30496789
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to "Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later".
    van Esch HJ; Geijteman ECT; van der Rijt CCD
    J Pain Symptom Manage; 2019 Apr; 57(4):e1-e2. PubMed ID: 30660674
    [No Abstract]   [Full Text] [Related]  

  • 5. Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide.
    Lowe JR; Hanson LC
    JAMA; 2021 Oct; 326(13):1263-1265. PubMed ID: 34609471
    [No Abstract]   [Full Text] [Related]  

  • 6. Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care.
    Wildiers H; Dhaenekint C; Demeulenaere P; Clement PM; Desmet M; Van Nuffelen R; Gielen J; Van Droogenbroeck E; Geurs F; Lobelle JP; Menten J;
    J Pain Symptom Manage; 2009 Jul; 38(1):124-33. PubMed ID: 19361952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic scopolamine butylbromide reduced death rattle in patients in the dying phase.
    Mechineni A
    Ann Intern Med; 2022 Mar; 175(3):JC31. PubMed ID: 35226526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyoscine butylbromide in labour.
    GARRETT AS; DRAPER VS
    Practitioner; 1963 May; 190():653-6. PubMed ID: 13960471
    [No Abstract]   [Full Text] [Related]  

  • 9. Prophylactic Scopolamine Butylbromide and Death Rattle in Patients at the End of Life.
    Abe A; Amano K; Ishiki H
    JAMA; 2022 Jan; 327(3):285. PubMed ID: 35040894
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylactic Scopolamine Butylbromide and Death Rattle in Patients at the End of Life-Reply.
    van Esch HJ; van Zuylen L; van der Rijt CCD
    JAMA; 2022 Jan; 327(3):285-286. PubMed ID: 35040890
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyoscine butylbromide and progress of labor in primigravidae: methodological concerns.
    Abbas AM
    J Matern Fetal Neonatal Med; 2019 Mar; 32(5):876. PubMed ID: 28918690
    [No Abstract]   [Full Text] [Related]  

  • 12. [The treatment of spastic states with hyoscine-N-butylbromide].
    HARTMANN HG
    Z Arztl Fortbild (Jena); 1953 Aug; 47(15):541-3. PubMed ID: 13090960
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of hyoscine butylbromide on the duration and progress of labor in primigravidae: a randomized controlled trial: methodological issues.
    Ranjbaran M
    J Matern Fetal Neonatal Med; 2019 Mar; 32(6):1049. PubMed ID: 29046122
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to: The effect of hyoscine butylbromide on the duration and progress of labor in primigravidae: a randomized controlled trial: methodological issues.
    Maged A
    J Matern Fetal Neonatal Med; 2019 Mar; 32(6):1020-1021. PubMed ID: 29057697
    [No Abstract]   [Full Text] [Related]  

  • 15. [Studies on the pharmacologic effect and clinical use of hyoscine-N-butylbromide (buscopan)].
    HEINKEL K
    Dtsch Z Verdau Stoffwechselkr; 1951 Jul; 11(4):180-95. PubMed ID: 14872696
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain.
    Tytgat GN
    Drugs; 2007; 67(9):1343-57. PubMed ID: 17547475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The muscle relaxant action of scopolamine butylbromide (buscopan)].
    PHILIPPOT E; DALLEMAGNE MJ
    Arch Int Pharmacodyn Ther; 1953 Apr; 93(3-4):337-40. PubMed ID: 13066127
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of Life: The SILENCE Randomized Clinical Trial.
    van Esch HJ; van Zuylen L; Geijteman ECT; Oomen-de Hoop E; Huisman BAA; Noordzij-Nooteboom HS; Boogaard R; van der Heide A; van der Rijt CCD
    JAMA; 2021 Oct; 326(13):1268-1276. PubMed ID: 34609452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presumed central anticholinergic syndrome from inadvertent intravenous hyoscine hydrobromide (scopolamine) injection.
    Wilden J; Rapeport D
    Anaesth Intensive Care; 2004 Jun; 32(3):419-22. PubMed ID: 15264742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to the letter: Evaluation of hyoscine N-butyl bromide efficacy on the prevention of catheter-related bladder discomfort after transurethral resection of prostate: a prospective randomized, double-blind control trial.
    Fard GS; Zand F; Asadpour E; Ghorbani M; Adibi P; Hosseini MM; Zeyghami S; Masihi F
    Int Urol Nephrol; 2018 Aug; 50(8):1447. PubMed ID: 29961177
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.